Ignite Creation Date:
2024-05-06 @ 11:35 AM
Last Modification Date:
2024-10-26 @ 12:47 PM
Study NCT ID:
NCT03559660
Status:
AVAILABLE
Last Update Posted:
2023-08-01
First Post:
2018-06-05
Brief Title:
CUP Certolizumab Pegol CDP-870 in Adults Suffering From Crohns Disease CD
Sponsor:
UCB Biopharma SRL
Organization:
UCB Pharma
Study Overview
Official Title:
Compassionate Use Program Certolizumab Pegol CDP-870 in Adults Suffering From Crohns Disease CD
Status:
AVAILABLE
Status Verified Date:
2023-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objective of this program is to allow treating physicians to supplycontinue to supply Certolizumab Pegol CIMZIA CZP to adults suffering from Crohns Disease CD and who are considered not suitable for treatment intolerant have medical contraindications or had insufficient response with an authorized conventional therapy including other authorized biologics
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None